2010 - TTS International Congress


This page contains exclusive content for the member of the following sections: TTS. Log in to view.

Molecular Mechanisms of Delayed Kidney Graft Function

119.2 - Hypoxia induced tubular cell (TEC) release of HMGB1 propagates renal injury by effects on TEC viability and NK cell activation

Presenter: Arthur, Lau, London, Canada
Authors: Lau A., Zhang Z., Wang S., Jevnikar A.

HYPOXIA INDUCED TUBULAR CELL (TEC) RELEASE OF HMGB1 PROPAGATES RENAL INJURY BY EFFECTS ON TEC VIABILITY AND NK CELL ACTIVATION

MOLECULAR MECHANISMS OF DELAYED KIDNEY GRAFT FUNCTION

A. Lau1, Z. Zhang2, S. Wang3, A.M. Jevnikar4
1Pathology, University of Western Ontario, London/ON/CANADA, 2Department Of Medicine, University of Western Ontario, London/CANADA, 3Department Of Medicine, Unuiversity of Western Ontario, London/CANADA, 4Department Of Medicine, Multi-Organ Transplant Program-London Health Sciences Centre, London/CANADA

Body: INTRODUCTION: Ischemia reperfusion injury (IRI) occurs in all transplanted kidneys as a consequence of organ procurement. With IRI, the death of kidney epithelial cells (TEC) and other parenchymal cells releases High Mobility Group Box-1 (HMGB1) and other damage associated molecular pattern (DAMP) proteins that promote inflammation by known effects on dendritic and infiltrating immune cells. However the role of DAMPs in propagating renal injury by effects on viable TEC remains unknown. METHODS/RESULTS: Uni-nephrectomized C57BL/6J mice were subjected to clamping of the remaining renal pedicle for 45 min to induce IRI. In western blot analyses, HMGB1 increased progressively in kidney samples in 24 hours post ischemia (naïve density ratio: 0.953±0.7107 vs. 24h post IRI density ratio: 5.3768±0.2439, p<0.001, n=3) without a change in HMGB1 mRNA expression. Correspondingly there was increased mRNA expression of TLR4, a key receptor for HMGB1 up to 24 hours post ischemia (relative fold increase: 4.654±2.554). Released extracellular HMGB1 was evident diffusely in sections by immuno-histochemistry, including tubular lumen. In vitro, TEC lines (NG1.1) subjected to hypoxia (2-5% oxygen for 20 min) underwent death (co-Annexin V/PI positivity) and progressively released HMGB1 into the supernatant up to 24 hours post ischemia (density ratio: 0.574 in no treatment vs. 8.88 in 24h post hypoxia). Conditioned media from hypoxia exposed TEC induced death in untreated TEC when added to viable monolayers and Annexin V/PI positivity was increased (media control: 36.1±4.4% vs. conditioned media: 51.25±9.75%). In addition to reducing survival of viable TEC, hypoxia induced TEC to a 6.86±2.067 fold increase of monocyte chemotactic protein-1 (MCP-1) mRNA expression at 24 hours compared to no treatment. Similarly, MCP-1 mRNA increased in vivo up to 24h after IRI (sham: 1±0 vs. 24h post IRI: 8.6328±3.56). Glycyrrhizic acid (GZA), a functional inhibitor of HMGB1 prevented this increase in hypoxic TEC in vitro in a dose dependent manner and reduced MCP-1 mRNA expression to levels observed in naive TEC (800ng/mL GZA: 1.587±0.345 vs. 24h post hypoxia: 6.86±2.067 ), indicating that the effect of HMGB1 on MCP-1 was mediated by preventing interaction with DAMP receptors on viable TEC. We found that MCP-1 is a chemoattractant for Natural Killer (NK) cells in transwell assay (migration index=4.19). In previous studies we have shown that NK cells are important effector cells in kidney IRI. To test the effect of DAMP on NK cells activation, purified NK cells were exposed to highly purified endotoxin free HMGB1, and showed subsequently mRNA increase in IFN-γ (2.51±0.52 vs. naïve NK cells, p<0.05, n=3) and Granzyme B (2.43±0.58 vs. naïve NK cells, p<0.05, n=3). CONCLUSION: These data demonstrate for the first time that HMGB1 released following hypoxic kidney injury has a previously unrecognized capacity to propagate renal injury by altering the survival of TEC as well as attracting and activating NK cells. Inhibition of HMGB1 release by TEC or blocking HMGB1 interaction with TEC may provide a therapeutic strategy that could limit renal IRI following transplantation.

Disclosure: All authors have declared no conflicts of interest.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada